CureVac

Line

• Director: Ingmar Hoerr

CureVac GmbH is a biopharmaceutical company from Tübingen, focused on the exploration and development of innovative medicines on the basis of messenger RNA ( mRNA) is specialized. The company focuses on new therapeutic approaches for the treatment of solid tumors through the use of sequence- optimized mRNA ( " RNActive "). Worldwide for the first time patients have been treated with mRNA in Phase-I/IIa-Studien in several countries (Italy, Switzerland, Germany and the USA) in the indications of prostate cancer and lung cancer. For patients with castration-resistant prostate cancer, a randomized phase IIb clinical trial with up to 200 patients in several European countries in March 2013 was started.

Furthermore CureVac developed at the mRNA based prophylactic vaccines against infections, here is collaborating with Sanofi- Pasteur company Tübingen ( Sanofi -Aventis Group ), one of the world leader in vaccines. In addition CureVac developed an immune stimulant ( adjuvant ) based on RNA to enhance the effect of prophylactic and therapeutic vaccines. In November 2012 CureVac has published together with the Friedrich- Loeffler -Institut data to an mRNA-based flu vaccine in the journal Nature Biotechnology. This vaccine may cause a life-long protection, but he has yet to be tested in large clinical studies .. October 2013 CureVac has entered into a collaboration to develop an influenza vaccine with the pharmaceutical company Johnson & Johnson.

History

2000 CureVac was founded at the University of Tübingen from the groups of Hans -Georg Rammensee and Günther Jung. In 2003 the company moved 18 employees into the Biotechnology Center Tübingen. In 2012 there were already 100 people.

CureVac has collected a total of 145 million euros of capital, of which 80 million euros in September 2012 by SAP co-founder Dietmar Hopp.

Awards

In 2007 CureVac received the Innovation Award of Baden -Württemberg and was also the winner of the nationwide Weconomy contest, which is awarded jointly by the Handelsblatt and the Knowledge Factory. Also CureVac received along with the research partners NMI nationwide Cooperation Award of the VBU DECHEMA for innovative approaches to immunotherapy.

On March 10, 2014, the company was awarded the first ever and doped with 2 million Euro Innovation Award of the European Commission for a new vaccine technology based on the messenger RNA ( mRNA).